Bangalore, May 21: Healthcare Global Enterprises Limited (HCG), India’s largest dedicated cancer hospital network, under the brand “HCG”, announced its financial results for the quarter and full year ended 31st March 2026.
RESULTS HIGHLIGHTS (Consolidated)
|
Particulars (Rs. Mn.) |
Q4FY26 |
Q4FY25 |
YoY |
FY26 |
FY25 |
YoY |
|
Revenue from Operations |
6,523 |
5,852 |
11% |
25,454 |
22,228 |
15% |
|
Adjusted EBITDA1 |
1,252 |
1,070 |
17% |
4,711 |
3,963 |
19% |
|
Margin (%) |
19.2 |
18.3 |
+91 bps |
18.5 |
17.8 |
+68 bps |
|
Adjusted PAT2 |
341 |
74 |
363% |
557 |
444 |
25% |
(1) Normalized for ESOP and one-time expenses, (2) Post Non-controlling interest normalized for one-time exceptional item pertaining to the impact of the new Labour code and impairment of goodwill
Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd., said “Cancer care is no longer only about treatment – it is about early diagnosis, precision, continuity of care, and improving quality of life for patients and families. Over the years, HCG has built a strong oncology ecosystem anchored in clinical excellence, multidisciplinary expertise, technology, and compassionate patient care. What differentiates us is our ability to bring together specialists, advanced diagnostics, research, and personalized treatment pathways under one integrated platform.
As we look ahead, our focus is on strengthening next-generation oncology capabilities across precision medicine, molecular diagnostics, genomics, robotics, and data-driven clinical decision-making. These advancements will play a critical role in detecting cancer earlier, reducing recurrence, improving outcomes, and making personalized cancer care more accessible to patients across India.
India has a significant opportunity to redefine the future of cancer care, and HCG remains committed to contributing meaningfully to this transformation through innovation, research, academic collaborations, and expansion of centres of excellence delivering globally benchmarked outcomes. Our purpose continues to remain clear – to make high-quality cancer care affordable, accessible, and patient-centric, while positively impacting millions of lives.”
Commenting on the results, Dr. Manish Mattoo, CEO, HealthCare Global Enterprises Ltd. said, “We concluded FY26 on a strong note, with our Q4 and full-year performance reflecting consistent execution across our network and reinforcing our conviction in the strength and distinctiveness of HCG’s cancer-focused platform. For the full year, revenues grew by 15% to Rs. 25,454 mn, with performance remaining well-balanced across regional clusters, supported by resilient demand for high-quality oncology care across medical, radiation, and surgical modalities.
Adjusted EBITDA for FY26 grew by 19% to Rs. 4,711 mn, with margins at 18.5%, reflecting operating leverage driven by improving throughput, better capacity utilisation, and disciplined cost management. This strong performance was sustained in Q4 FY26, with adjusted EBITDA increasing by 17% to Rs. 1,252 mn and margins expanding to 19.2%, underscoring continued momentum in operating performance. Overall, our performance demonstrates the scalability of our model and the depth of our clinical capabilities, backed by a sustained focus on outcomes and patient-centric care.
A key milestone during the year was the successful completion of our Rs. 4,250 mn rights issue, which further strengthened our financial foundation and gives us greater flexibility to invest behind our long-term priorities – including capacity expansion, clinical infrastructure upgrades, technology investments and selective growth opportunities – while continuing to maintain a disciplined, returns-focused approach.
HCG’s integrated care model continues to be a key differentiator, anchored in tumour-board-led clinical decision-making, consistent clinical outcomes, and the trust built over more than two decades. We remain focused on driving higher asset utilisation, deepening clinical excellence, and expanding our network selectively, while staying anchored to our core purpose of delivering high-quality, accessible cancer care.”